The Potential for Harm Is Real

Visiting scholar Marcin Waligora coauthors study on early-stage pediatric cancer therapies

The bar for clinical trials involving children, by design, is set higher than it is for adults. Before a drug can be given to children in a Phase 1 trial, it must have already been tested in adults and shown some signals about its safety and clinical promise. That, however, does not mean the outcomes will be any better, according to a new study.

Study first author Marcin Waligora is a Fullbright visiting scholar at the Center. He is associate professor of philosophy and bioethics at Jagiellonian University Medical College.

Read the full story.